EirGenix

Highly Engaged Employees

EirGenix has been providing CDMO services since its establishment in 2013. In less than 7 years, the company has seen its operating income grow to a record high of 400 million New Taiwan Dollars in 2019, with its gross profit also reaching a record high. This year, EirGenix will continue to undertake even more contracts entrusted to it by internati... onal biotech and pharmaceutical companies from all over the world, including Japan, the United States, MainlandChina, and Europe. In its pioneer years, EirGenix primarily served the local Taiwanese market, but quickly expanded its business outside Taiwan to become the international CDMO company it is today. Now with the announcement of PMDA's authorization for EirGenix to manufacture marketed drug substances in Japan, EirGenix further expands its offerings to a more robust service life cycle, from early-stage research and development up to commercial manufacturing of marketed products. EirGenix's greater one-stop CDMO service offerings are certain to provide it with the competitive advantage to compete with other international companies on the global market.Read More